Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Recent advances in microneedles for enhanced functional angiogenesis and vascular drug delivery

Nguyen NH., Nguyen TT., Bui VKH., Nguyen NTT., Van Vo G.

Narrative Review on Chronic Wound, published in Ther Deliv (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Ther Deliv (2025)
Reported sample size
—
Source database
Europe PMC
PMID
39997030
PMCID
PMC11970790
DOI
10.1080/20415990.2025.2468148
Citations
2

Abstract (original English)

Many therapeutic applications use the transdermal method to avoid the severe restrictions associated with oral medication delivery. Given the limitations of traditional drug delivery via skin, transdermal microneedle (MN) arrays have been reported to be versatile and very efficient devices due to their outstanding characteristics such as painless penetration, affordability, excellent medicinal efficacy, and relative safety. MNs have recently received increased attention for their ability to cure vascular illnesses such as hypertension and thrombosis, as well as promote wound healing via the angiogenesis impact. The integrant of method manufacturing and biodegradable material allows for the modification of MN form and drug release pattern, hence increasing the flexibility of such drug delivery. In this review, we focused on recent improvements in MN-mediated transdermal administration of protein and peptide medicines for improved functional angiogenesis and vascular therapy. We also provide an overview of the present applications of MNs-mediated transdermal protein and peptide administration, particularly in the realm of vascular system disease therapy. Finally, the current state of clinical translation and a forecast for future progress are provided.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansPeptidesDrug Delivery SystemsAdministration, CutaneousMicroinjectionsNeedlesNeovascularization, PhysiologicAngiogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research